Profile picture

Assistant Professor Alexander Peikert

Medical University of Graz, Graz (Austria)
Membership: FESC Member
Follow
Biography
Alexander Peikert is an Assistant Professor of cardiology and board-certified cardiologist at the University Heart Center Graz of the Medical University of Graz, Austria. His research interests focus on clinical trials, cardio-renal-metabolic disease, and pharmacotherapy. He graduated and earned his MD at the University of Freiburg, Germany. He trained in internal medicine and cardiology at the University Heart Center Freiburg, Germany, and the University Heart Center Graz, Austria. He completed a postdoctoral research fellowship at the Brigham and Women’s Hospital and Harvard Medical School in Boston, MA, USA. He is involved in the conduct, analyses, and reporting of multiple international randomized clinical trials. He is a Future Trialists Fellow of the Global CardioVascular Clinical Trialists Forum. He has authored numerous peer-reviewed publications in leading high-impact journals. He serves as Deputy Editor for the European Journal of Preventive Cardiology.
Logo ESC

Contributor content

Effect of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction treated with beta-blockers: the DELIVER trial
Presentation
Effect of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction treated with beta-blockers: the DELIVER trial
Efficacy and safety of dapagliflozin in the background of polypharmacy among patients with HFmrEF and HFpEF in the DELIVER trial
Presentation
Efficacy and safety of dapagliflozin in the background of polypharmacy among patients with HFmrEF and HFpEF in the DELIVER trial
Effect of dapagliflozin on individual components of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
Presentation
Effect of dapagliflozin on individual components of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
Need of Treating Residual Inflammatory Activity in Coronary Heart Disease:  the value of high sensitive CRP and LDL in a Real World Cohort.
Presentation
Need of Treating Residual Inflammatory Activity in Coronary Heart Disease: the value of high sensitive CRP and LDL in a Real World Cohort.